MedTrace Logo

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

NCT00956436 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-09-16

No results posted yet for this study

Summary

This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

BIIB022

IV Q3W

DRUG

Sorafenib

Standard dosing of Sorafenib

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States
  • Singapore
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00956436 on ClinicalTrials.gov